Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 156 entries
Sorted by: Best Match Show Resources per page
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

OncoTargets and therapy

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.
PMID: 28919776
Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic...

Cite
Creelan BC, Gabrilovich DI, Gray JE, et al. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250doi: 10.2147/OTT.S136992.
Creelan, B. C., Gabrilovich, D. I., Gray, J. E., Williams, C. C., Tanvetyanon, T., Haura, E. B., Weber, J. S., Gibney, G. T., Markowitz, J., Proksch, J. W., Reisman, S. A., McKee, M. D., Chin, M. P., Meyer, C. J., & Antonia, S. J. (2017). Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. OncoTargets and therapy, 104239-4250. https://doi.org/10.2147/OTT.S136992
Creelan, Ben C, et al. "Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors." OncoTargets and therapy vol. 10 (2017): 4239-4250. doi: https://doi.org/10.2147/OTT.S136992
Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017. PMID: 28919776; PMCID: PMC5587199.
Copy Download .nbib Format: NLM
Delayed Intracerebral Hemorrhage from a Pseudoaneurysm Following a Depressed Skull Fracture.

Neurointervention

Nazari P, Kasliwal MK, Wewel JT, Dua SG, Chen M.
PMID: 26958412
Neurointervention. 2016 Mar;11(1):42-5. doi: 10.5469/neuroint.2016.11.1.42. Epub 2016 Mar 03.

A 26-year-old male presented with delayed intracerebral hemorrhage from a ruptured distal middle cerebral artery pseudoaneurysm that followed a compound depressed skull fracture from years ago. The brain protrusion through the skull defect likely resulted in stretching and subsequent...

Cite
Nazari P, Kasliwal MK, Wewel JT, et al. Delayed Intracerebral Hemorrhage from a Pseudoaneurysm Following a Depressed Skull Fracture. Neurointervention. 2016;11(1):42-5doi: 10.5469/neuroint.2016.11.1.42.
Nazari, P., Kasliwal, M. K., Wewel, J. T., Dua, S. G., & Chen, M. (2016). Delayed Intracerebral Hemorrhage from a Pseudoaneurysm Following a Depressed Skull Fracture. Neurointervention, 11(1), 42-5. https://doi.org/10.5469/neuroint.2016.11.1.42
Nazari, Pouya, et al. "Delayed Intracerebral Hemorrhage from a Pseudoaneurysm Following a Depressed Skull Fracture." Neurointervention vol. 11,1 (2016): 42-5. doi: https://doi.org/10.5469/neuroint.2016.11.1.42
Nazari P, Kasliwal MK, Wewel JT, Dua SG, Chen M. Delayed Intracerebral Hemorrhage from a Pseudoaneurysm Following a Depressed Skull Fracture. Neurointervention. 2016 Mar;11(1):42-5. doi: 10.5469/neuroint.2016.11.1.42. Epub 2016 Mar 03. PMID: 26958412; PMCID: PMC4781916.
Copy Download .nbib Format: NLM
Chemotherapy-related changes in cognitive functioning.

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Schagen SB, Wefel JS.
PMID: 26217131
EJC Suppl. 2013 Sep;11(2):225-32. doi: 10.1016/j.ejcsup.2013.07.007.

No abstract available.

Cite
Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. EJC Suppl. 2013;11(2):225-32doi: 10.1016/j.ejcsup.2013.07.007.
Schagen, S. B., & Wefel, J. S. (2013). Chemotherapy-related changes in cognitive functioning. EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.], 11(2), 225-32. https://doi.org/10.1016/j.ejcsup.2013.07.007
Schagen, Sanne B, and Wefel, Jeffrey S. "Chemotherapy-related changes in cognitive functioning." EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] vol. 11,2 (2013): 225-32. doi: https://doi.org/10.1016/j.ejcsup.2013.07.007
Schagen SB, Wefel JS. Chemotherapy-related changes in cognitive functioning. EJC Suppl. 2013 Sep;11(2):225-32. doi: 10.1016/j.ejcsup.2013.07.007. PMID: 26217131; PMCID: PMC4041313.
Copy Download .nbib Format: NLM
Research, robots, and reality: A statement on current trends in biorobotics.

The Behavioral and brain sciences

Niebur E, Elhilali M, Obeid I, Werfel J, Blanchard M, Frasca M, Ghose K, Hofstoetter C, Indiveri G, Tilden MW.
PMID: 18241384
Behav Brain Sci. 2001 Dec;24(6):1072-1073. doi: 10.1017/S0140525X01450126.

While robotics has benefited from inspiration gained from biology, the opposite is not the case: there are few if any cases in which robotic models have lead to genuine insight into biology. We analyze the reasons why biorobotics has...

Cite
Niebur E, Elhilali M, Obeid I, et al. Research, robots, and reality: A statement on current trends in biorobotics. Behav Brain Sci. 2001;24(6):1072-1073doi: 10.1017/S0140525X01450126.
Niebur, E., Elhilali, M., Obeid, I., Werfel, J., Blanchard, M., Frasca, M., Ghose, K., Hofstoetter, C., Indiveri, G., & Tilden, M. W. (2001). Research, robots, and reality: A statement on current trends in biorobotics. The Behavioral and brain sciences, 24(6), 1072-1073. https://doi.org/10.1017/S0140525X01450126
Niebur, Ernst, et al. "Research, robots, and reality: A statement on current trends in biorobotics." The Behavioral and brain sciences vol. 24,6 (2001): 1072-1073. doi: https://doi.org/10.1017/S0140525X01450126
Niebur E, Elhilali M, Obeid I, Werfel J, Blanchard M, Frasca M, Ghose K, Hofstoetter C, Indiveri G, Tilden MW. Research, robots, and reality: A statement on current trends in biorobotics. Behav Brain Sci. 2001 Dec;24(6):1072-1073. doi: 10.1017/S0140525X01450126. PMID: 18241384.
Copy Download .nbib Format: NLM
Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Weber JS.
PMID: 24451730
Am Soc Clin Oncol Educ Book. 2012;174-7. doi: 10.14694/EdBook_AM.2012.32.79.

Monoclonal antibodies directed against immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1), can boost endogenous immune responses directed against tumor cells. Recently, ipilimumab was approved by the U.S. Food and Drug Administration (FDA) for...

Cite
Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012;174-7doi: 10.14694/EdBook_AM.2012.32.79.
Weber, J. S. (2012). Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 174-7. https://doi.org/10.14694/EdBook_AM.2012.32.79
Weber, Jeffrey S. "Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist." American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting vol. (2012): 174-7. doi: https://doi.org/10.14694/EdBook_AM.2012.32.79
Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012;174-7. doi: 10.14694/EdBook_AM.2012.32.79. PMID: 24451730.
Copy Download .nbib Format: NLM
Observation of associated bottom production and decay in a high-energy hadron interaction.

Physical review. D, Particles and fields

Burnett TH, Dake S, Fuki M, Gregory JC, Hayashi T, Holynski R, Iwai J, Jezabek M, Jones WV, Jurak A, Lord JJ, Miyamura O, Oda H, Ogata T, Parnell TA, Strausz SC, Tabuki T, Takahashi Y, Tominaga T, Wefel JP, Wilczynska B, Wilczynski H, Wilkes RJ, Wolter W, Wosiek B.
PMID: 10012271
Phys Rev D Part Fields. 1990 Jun 01;41(11):3336-3342. doi: 10.1103/physrevd.41.3336.

No abstract available.

Cite
Burnett TH, Dake S, Fuki M, et al. Observation of associated bottom production and decay in a high-energy hadron interaction. Phys Rev D Part Fields. 1990;41(11):3336-3342doi: 10.1103/physrevd.41.3336.
Burnett, T. H., Dake, S., Fuki, M., Gregory, J. C., Hayashi, T., Holynski, R., Iwai, J., Jezabek, M., Jones, W. V., Jurak, A., Lord, J. J., Miyamura, O., Oda, H., Ogata, T., Parnell, T. A., Strausz, S. C., Tabuki, T., Takahashi, Y., Tominaga, T., Wefel, J. P., Wilczynska, B., Wilczynski, H., Wilkes, R. J., Wolter, W., & Wosiek, B. (1990). Observation of associated bottom production and decay in a high-energy hadron interaction. Physical review. D, Particles and fields, 41(11), 3336-3342. https://doi.org/10.1103/physrevd.41.3336
Burnett, et al. "Observation of associated bottom production and decay in a high-energy hadron interaction." Physical review. D, Particles and fields vol. 41,11 (1990): 3336-3342. doi: https://doi.org/10.1103/physrevd.41.3336
Burnett TH, Dake S, Fuki M, Gregory JC, Hayashi T, Holynski R, Iwai J, Jezabek M, Jones WV, Jurak A, Lord JJ, Miyamura O, Oda H, Ogata T, Parnell TA, Strausz SC, Tabuki T, Takahashi Y, Tominaga T, Wefel JP, Wilczynska B, Wilczynski H, Wilkes RJ, Wolter W, Wosiek B. Observation of associated bottom production and decay in a high-energy hadron interaction. Phys Rev D Part Fields. 1990 Jun 01;41(11):3336-3342. doi: 10.1103/physrevd.41.3336. PMID: 10012271.
Copy Download .nbib Format: NLM
Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities.

Neuro-oncology practice

Wefel JS.
PMID: 31385963
Neurooncol Pract. 2018 Nov;5(4):203. doi: 10.1093/nop/npy045. Epub 2018 Nov 02.

No abstract available.

Cite
Wefel JS. Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neurooncol Pract. 2018;5(4):203doi: 10.1093/nop/npy045.
Wefel, J. S. (2018). Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neuro-oncology practice, 5(4), 203. https://doi.org/10.1093/nop/npy045
Wefel, Jeffrey S. "Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities." Neuro-oncology practice vol. 5,4 (2018): 203. doi: https://doi.org/10.1093/nop/npy045
Wefel JS. Food for thought: patient outcomes, diagnostic challenges, and therapeutic possibilities. Neurooncol Pract. 2018 Nov;5(4):203. doi: 10.1093/nop/npy045. Epub 2018 Nov 02. PMID: 31385963; PMCID: PMC6656306.
Copy Download .nbib Format: NLM
Choosing clinical trial endpoints, aggregating data, and making clinical decisions.

Neuro-oncology practice

Wefel JS.
PMID: 31385989
Neurooncol Pract. 2017 Dec;4(4):199-200. doi: 10.1093/nop/npx032. Epub 2017 Dec 01.

No abstract available.

Cite
Wefel JS. Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neurooncol Pract. 2017;4(4):199-200doi: 10.1093/nop/npx032.
Wefel, J. S. (2017). Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neuro-oncology practice, 4(4), 199-200. https://doi.org/10.1093/nop/npx032
Wefel, Jeffrey S. "Choosing clinical trial endpoints, aggregating data, and making clinical decisions." Neuro-oncology practice vol. 4,4 (2017): 199-200. doi: https://doi.org/10.1093/nop/npx032
Wefel JS. Choosing clinical trial endpoints, aggregating data, and making clinical decisions. Neurooncol Pract. 2017 Dec;4(4):199-200. doi: 10.1093/nop/npx032. Epub 2017 Dec 01. PMID: 31385989; PMCID: PMC6655419.
Copy Download .nbib Format: NLM
[No title available]

Neuro-oncology practice

Wefel JS.
PMID: 31386053
Neurooncol Pract. 2016 Dec;3(4):209-210. doi: 10.1093/nop/npw024. Epub 2016 Nov 01.

No abstract available.

Cite
Wefel JS. . Neurooncol Pract. 2016;3(4):209-210doi: 10.1093/nop/npw024.
Wefel, J. S. (2016). . Neuro-oncology practice, 3(4), 209-210. https://doi.org/10.1093/nop/npw024
Wefel, Jeffrey S. "." Neuro-oncology practice vol. 3,4 (2016): 209-210. doi: https://doi.org/10.1093/nop/npw024
Wefel JS. . Neurooncol Pract. 2016 Dec;3(4):209-210. doi: 10.1093/nop/npw024. Epub 2016 Nov 01. PMID: 31386053; PMCID: PMC6657398.
Copy Download .nbib Format: NLM
Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy.

Neuro-oncology practice

Wefel JS.
PMID: 31386055
Neurooncol Pract. 2019 Jul;6(4):247-248. doi: 10.1093/nop/npz035. Epub 2019 Jul 27.

No abstract available.

Cite
Wefel JS. Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neurooncol Pract. 2019;6(4):247-248doi: 10.1093/nop/npz035.
Wefel, J. S. (2019). Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neuro-oncology practice, 6(4), 247-248. https://doi.org/10.1093/nop/npz035
Wefel, Jeffrey S. "Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy." Neuro-oncology practice vol. 6,4 (2019): 247-248. doi: https://doi.org/10.1093/nop/npz035
Wefel JS. Opportunities to enhance our management, outcomes, and interventions for patients with CNS malignancy. Neurooncol Pract. 2019 Jul;6(4):247-248. doi: 10.1093/nop/npz035. Epub 2019 Jul 27. PMID: 31386055; PMCID: PMC6660814.
Copy Download .nbib Format: NLM
Comment on the American Society of Clinical Oncology Value Statement.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Weber JS, Drakeman DL.
PMID: 27298417
J Clin Oncol. 2016 Aug 20;34(24):2937-8. doi: 10.1200/JCO.2015.64.3692. Epub 2016 Jun 13.

No abstract available.

Cite
Weber JS, Drakeman DL. Comment on the American Society of Clinical Oncology Value Statement. J Clin Oncol. 2016;34(24):2937-8doi: 10.1200/JCO.2015.64.3692.
Weber, J. S., & Drakeman, D. L. (2016). Comment on the American Society of Clinical Oncology Value Statement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(24), 2937-8. https://doi.org/10.1200/JCO.2015.64.3692
Weber, Jeffrey S, and Drakeman, Donald L. "Comment on the American Society of Clinical Oncology Value Statement." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 34,24 (2016): 2937-8. doi: https://doi.org/10.1200/JCO.2015.64.3692
Weber JS, Drakeman DL. Comment on the American Society of Clinical Oncology Value Statement. J Clin Oncol. 2016 Aug 20;34(24):2937-8. doi: 10.1200/JCO.2015.64.3692. Epub 2016 Jun 13. PMID: 27298417.
Copy Download .nbib Format: NLM
A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States.

MDM policy & practice

Swan JS, Lennes IT, Stump NN, Temel JS, Wang D, Keller L, Donelan K.
PMID: 30349874
MDM Policy Pract. 2018 Oct 15;3(2):2381468318801565. doi: 10.1177/2381468318801565. eCollection 2018.

No abstract available.

Cite
Swan JS, Lennes IT, Stump NN, et al. A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States. MDM Policy Pract. 2018;3(2):2381468318801565doi: 10.1177/2381468318801565.
Swan, J. S., Lennes, I. T., Stump, N. N., Temel, J. S., Wang, D., Keller, L., & Donelan, K. (2018). A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States. MDM policy & practice, 3(2), 2381468318801565. https://doi.org/10.1177/2381468318801565
Swan, J Shannon, et al. "A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States." MDM policy & practice vol. 3,2 (2018): 2381468318801565. doi: https://doi.org/10.1177/2381468318801565
Swan JS, Lennes IT, Stump NN, Temel JS, Wang D, Keller L, Donelan K. A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States. MDM Policy Pract. 2018 Oct 15;3(2):2381468318801565. doi: 10.1177/2381468318801565. eCollection 2018. PMID: 30349874; PMCID: PMC6194926.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 156 entries